View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 24, 2020updated 06 Jan 2021 8:43am

Novellus and Tempus to accelerate patient enrolment for trials

Clinical-stage biotechnology company Novellus and technology company Tempus have announced collaboration to accelerate patient enrollment for the former’s BRAF trial.

Clinical-stage biotechnology company Novellus and technology company Tempus have announced collaboration to accelerate patient enrollment for the former’s BRAF trial.

The next generation BRAF inhibitor programme, which is in clinical trial, focuses on patient populations for which no FDA-approved BRAF inhibitors are currently available.

These inhibitors include BRAF fusions and BRAF-mutated gliomas.

Novellus CEO Michael Vidne said: “The collaboration with Tempus will enable us to accelerate the enrollment of patients in our BRAF trial, by precisely identifying potential candidates and opening sites wherever the patients are found.”

The company will take part in Tempus’s TIME Trial Network. Together, Novellus and Tempus will work to identify relevant patients for accelerating enrollment of patients.

Tempus chief medical officer Kim Blackwell said: “The TIME Trial Program has achieved an unparalleled scale thus far, with over 50 provider networks and 2,500 oncologists included in its network.

“We’re excited to collaborate with Novellus, to further our mission to increase trial participation, and to ultimately bring the right treatment to the right patients at the right time.”

Novellus focuses on the development of compounds for established oncogene drivers with a high incidence of uncharacterised mutations.

In September this year, LabCorp announced a collaboration with Tempus’ drug development business, Covance to participate in its TIME Trial Network.

Under the collaboration, the companies also agreed to work together to accelerate patient enrollment for oncology clinical trials.

Tempus unveiled the TIME trial service in June last year to match cancer patients to clinical trials. TIME trial aims to increase clinical trial participation of cancer patients treated in both the academic and community setting.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena